Retinopati Klorokuin dan Hidroksiklorokuin
DOI:
https://doi.org/10.55175/cdk.v47i8.591Kata Kunci:
Hidroksiklorokuin, klorokuin, retinopatiAbstrak
Klorokuin dan hidroksiklorokuin kerap digunakan sebagai tatalaksana berbagai penyakit autoimun, infeksi malaria, dan kini menjadi salah satu obat penanggulangan darurat Coronavirus Disease-19 (COVID-19). Kedua obat ini berpotensi sebagai antiinflamasi dan antivirus. Namun penggunaannya sering menimbulkan berbagai efek samping seperti pada jantung, saraf, saluran pencernaan, dan mata. Efek samping pada mata dapat berupa toksisitas retina yang dapat berakhir menjadi retinopati ireversibel. Guna menghindari cacat permanen, diperlukan pencegahan yang tepat dengan mengenali faktor risiko dan skrining, serta pemantauan ketat penggunaan obat.
Chloroquine and hydroxychloroquine are often used as a treatment for autoimmune disease, malaria infection, and now become an emergency drug for Coronavirus Disease-19 (COVID-19). Both are potential anti-inflammatory and antiviral agents. However, potential various side effects to the heart, nerves, gastrointestinal tract, and also eyes must be considered. Side effects on the eyes are retinal toxicity which can end up as irreversible retinopathy. Proper prevention is needed by recognizing risk factors and screening, as well as strict monitoring of drug use. I
Unduhan
Referensi
Schrezenmeier E, Dörner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol. 2020;16(3):155–66.
Peponis V, Kyttaris VC, Chalkiadakis SE, Bonovas S, Sitaras NM. Ocular side effects of anti-rheumatic medications: What a rheumatologist should know. Lupus 2010;19(6):675–82.
Stokkermans TJ, Trichonas G. Chloroquine and hydroxychloroquine toxicity. In: StatPearls. Treasure Island (FL); 2020.
Zhang W, Zhao Y, Zhang F, Wang Q, Li T, Liu Z, et al. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China. Clin Immunol Orlando Fla. 2020;214(2020):108393.
Devaux CA, Rolain J-M, Colson P, Raoult D. New insights on the antiviral effects of chloroquine against coronavirus: What to expect for COVID-19? Int J Antimicrob Agents. 2020;105938.
Kementerian Kesehatan RI. Info infeksi emerging Kementerian Kesehatan RI [Internet]. 2020. Available from: https://covid19.kemkes.go.id/.
National institutes of health. Coronavirus disease 2019 (COVID-19) treatment guidelines [Internet]. 2020. Available from: https://www.covid19treatmentguidelines.nih.gov/whats-new/.
Braga C, Martins A, Cayotopa A, Klein W, Schlosser A, Silva A, et al. Side effects of chloroquine and primaquine and symptom reduction in malaria endemic area (Mâncio Lima, Acre, Brazil). Interdiscip Perspect Infect Dis. 2015;2015:346853.
Hansen M, Schuman S. Hydroxychloroquine-induced retinal toxicity. Eyenet. 2011;33-5.
Singh AK, Singh A, Shaikh A, Singh R, Misra A. Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to India and other developing countries. Diabetes Metab Syndr. 2020;14(3):241–6.
Liu J, Cao R, Xu M, Wang X, Zhang H, Hu H, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov. 2020;6(1):1–4.
Keyaerts E, Li S, Vijgen L, Rysman E, Verbeeck J, Ranst MV, et al. Antiviral activity of chloroquine against human coronavirus OC43 infection in newborn mice. Antimicrob Agents Chemother. 2009;53(8):3416–21.
The Royal College of Ophthalmologists. Clinical guideline: Hydroxychloroquine and chloroquine retinopathy: Recommendations on monitoring. The Royal College of Ophthalmologists; 2020.
Hobbs HE, Sorsby A, Freedman A. Retinopathy following chloroquine therapy. Lancet. 1959;2(7101):478-80.
Bae EJ, Kim KR, Tsang SH, Park SP, Chang S. Retinal damage in chloroquine maculopathy, revealed by high resolution imaging: A case report utilizing adaptive optics scanning laser ophthalmoscopy. Korean J Ophthalmol KJO. 2014;28(1):100–7.
Leecharoen S, Wangkaew S, Louthrenoo W. Ocular side effects of chloroquine in patients with rheumatoid arthritis, systemic lupus erythematosus and scleroderma. J Med Assoc Thai. 2007;90(1):52-8.
Mirshahi A, Naderan M, Abrishami M. Screening for hydroxychloroquine-associated retinopathy: A review. JCDR. 2019;13(7):1-6.
Selim E, Elsawy S, Verma S, Auf R. Screening for hydroxychloroquine maculopathy. Adv Ophthalmol Vis Syst. 2019;9(6):147-9.
Dahrouj, M., Young, L. Hydroxychloroquine retinopathy in the era of advanced imaging modalities. ResearchGate. 2020;60(1):73-83.
Marmor MF, Kellner U, Lai TYY, Melles RB, Mieler WF. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 rev). Am Acad Ophthalmol. 2016;123(6):1386–94.
Pasaoglu I, Onmez FE. Macular toxicity after short-term hydroxychloroquine therapy. Indian J Ophthalmol. 2019;67(2):289–92.
Hernández Bel L, Monferrer Adsuara C, Hernández Garfella M, Cervera Taulet E. Early macular toxicity following 2 months of hydroxychloroquine therapy. Arch Soc Espanola Oftalmol. 2018;93(3):20–1.
Burhan E, Susanto AD, Nasution SA, Ginanjar E. Protokol tatalaksana covid-19. PDPI. PERKI, PAPDI, PERDATIN, IDAI; 2020
Unduhan
Diterbitkan
Cara Mengutip
Terbitan
Bagian
Lisensi
Hak Cipta (c) 2020 https://creativecommons.org/licenses/by-nc/4.0/
Artikel ini berlisensi Creative Commons Attribution-NonCommercial 4.0 International License.
